← Back to Search

Gallium-68 citrate, PET for Prostate Cancer

Phase < 1
Waitlist Available
Led By Rahul Aggarwal, MD
Research Sponsored by Rahul Aggarwal
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male participants with histologically confirmed prostate cancer
Participants must have castrate levels of testosterone (< 50 ng/dL) on Luteinizing hormone-releasing hormone (LHRH) analogue or have had prior bilateral orchiectomy, with evidence of castration-resistant disease by Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 weeks
Awards & highlights

Study Summary

This trial is investigating the use of gallium-68 citrate PET in patients with metastatic castration-resistant prostate cancer who are planning to undergo a metastatic tumor biopsy.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean maximum Standardized Uptake Value (SUVmax)
Mean maximum Standardized Uptake Value (SUVmax-ave)
Secondary outcome measures
Correlation between SUVmax and MYC gene expression
Correlation between SUVmax and transferrin receptor gene expression
Mean SUVmax-ave percent change from baseline
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Gallium-68 citrate, PETExperimental Treatment2 Interventions
Participants will receive a single scan obtained on a single day, followed by optional tumor biopsy within 6 weeks of scan. There will be optional follow up gallium-68 citrate PET scan to assess response to treatment received outside this study that will be completed within 12 weeks of baseline scan.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Gallium-68 citrate
2013
Completed Early Phase 1
~50
Positron Emission Tomography (PET)
2018
Completed Phase 4
~1390

Find a Location

Who is running the clinical trial?

Rahul AggarwalLead Sponsor
11 Previous Clinical Trials
481 Total Patients Enrolled
7 Trials studying Prostate Cancer
278 Patients Enrolled for Prostate Cancer
United States Department of DefenseFED
856 Previous Clinical Trials
225,556 Total Patients Enrolled
38 Trials studying Prostate Cancer
5,555 Patients Enrolled for Prostate Cancer
Rahul Aggarwal, MDPrincipal Investigator - University of California, San Francisco
UCSF Medical Center at Parnassus
Northwestern University Medical Sch (Medical School)
21 Previous Clinical Trials
1,354 Total Patients Enrolled
12 Trials studying Prostate Cancer
1,026 Patients Enrolled for Prostate Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this clinical trial still have availability for prospective participants?

"This medical trial, whose initial post date was May 28th 2015 and last update on June 22nd 2022, is currently closed to new participants. Nevertheless, 1260 additional trials are accepting patients as of now."

Answered by AI

What is the main purpose of this investigation?

"This medical trial will primarily assess SUVmax-ave over a single day period. Additionally, they are measuring the sensitivity of gallium citrate PET in comparison to bone scans; correlating SUVax and MYC gene expression for patients that opt into biopsy procedures; along with evaluating the specificity of gallium citrate PET against its counterpart imaging technique."

Answered by AI

How many participants is this medical experiment enlisting?

"Unfortunately, this experiment has concluded its participant recruitment. According to the information made available on clinicaltrials.gov, the trial was first listed May 28th 2015 and last updated June 22nd 2022. For those seeking similar studies, there are currently 1252 prostate cancer trials open for enrollment as well 8 Gallium-68 citrate PET investigations searching for volunteers."

Answered by AI

What conditions are often evaluated with Gallium-68 citrate PET scans?

"Gallium-68 citrate PET is a viable method of managing the symptoms associated with metabolic acidosis, calcinosis, and heartburn."

Answered by AI
~4 spots leftby Mar 2025